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Abstract 
Endocrine disrupting chemicals (EDCs) are xenobiotics which adversely modify the hormone system. The 
endocrine system is most vulnerable to assaults by endocrine disruptors during the prenatal and early 
development window, and effects may persist into adulthood and across generations. The prenatal stage 
is a period of vulnerability to environmental chemicals because the epigenome is usually reprogrammed 
during this period. Bisphenol A (BPA), lead (Pb), and dichlorodiphenyltrichloroethane (DDT) were chosen 
for critical review because they have become serious public health concerns globally, especially in Africa 
where they are widely used without any regulation. In this review, we introduce EDCs and describe the 
various modes of action of EDCs and the importance of the prenatal and developmental windows to EDC 
exposure. We give a brief overview of epigenetics and describe the various epigenetic mechanisms: DNA 
methylation, histone modifications and non-coding RNAs, and how each of them affects gene expression. 
We then summarize findings from previous studies on the effects of prenatal exposure to the endocrine 
disruptors BPA, Pb and DDT on each of the previously described epigenetic mechanisms. We also 
discuss how the epigenetic alterations caused by these EDCs may be related to disease processes. 
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